Opportunity Information: Apply for RFA DA 21 012
The NIH funding opportunity RFA-DA-21-012, titled "Elucidation of mechanisms underlying complex morbidities of SUD and other mental illnesses in people living with HIV/AIDS (R01 Clinical Trial Optional)," supports research aimed at explaining why substance use disorders (SUD) and other psychiatric conditions so often cluster together in people living with HIV (PLWHIV). The central goal is to move beyond simply documenting that these conditions co-occur and instead identify the neurobehavioral mechanisms that drive these complex, overlapping morbidities. In practice, this means encouraging studies that can clarify how brain function, behavior, and mental health processes interact with HIV-related factors to worsen risk, symptoms, and functional outcomes, and to do so in ways that can eventually inform better prevention and treatment strategies.
This opportunity uses the R01 grant mechanism, which typically funds substantial, multi-year, hypothesis-driven research projects. It is labeled "Clinical Trial Optional," meaning applicants may propose either clinical trial research or non-trial studies, depending on what is most appropriate for the mechanistic questions being pursued. The emphasis is on mechanism-focused work, particularly neurobehavioral pathways, which can include cognitive, affective, motivational, reward, stress, and self-regulation processes that link HIV, substance use, and co-occurring psychiatric disorders. The intent is to support studies that can disentangle causal and maintaining factors behind multimorbidity, rather than treating each diagnosis as separate or only describing correlations.
The sponsoring agency is the National Institutes of Health (NIH), and the program sits within the health-related federal assistance domain (CFDA 93.279). The activity category is listed under Education and Health, reflecting NIH's broader mission to fund research that advances knowledge and improves health outcomes. The opportunity is a discretionary grant, meaning awards are made through a competitive review process based on scientific merit and program priorities. The posting indicates an original closing date of January 6, 2021, with a creation date of October 16, 2020, which situates the announcement as a time-limited solicitation released for a specific receipt window.
A wide range of organizations are eligible to apply, which signals an intent to draw in diverse research settings and partnerships, including those with strong ties to populations disproportionately affected by HIV, SUD, and mental illness. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; and public housing authorities/Indian housing authorities. Nonprofit organizations are eligible whether they do or do not hold 501(c)(3) status, as are for-profit organizations (other than small businesses) and small businesses. Federally recognized Native American tribal governments and other Native American tribal organizations (including those other than federally recognized tribal governments) are also eligible. The announcement additionally highlights a broad set of other eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, eligible federal agencies, and even non-domestic (non-U.S.) entities (foreign organizations). This breadth is important because it encourages proposals that can reach varied communities, leverage specialized clinical cohorts, and incorporate culturally informed approaches and community-engaged research infrastructures.
Overall, the opportunity is focused on generating rigorous, mechanism-oriented evidence about how SUD and psychiatric disorders interact with HIV in the real world, particularly through neurobehavioral pathways. By prioritizing an understanding of underlying mechanisms in PLWHIV experiencing multimorbidity, the funding call is designed to support work that can ultimately improve clinical approaches, reduce compounded morbidity, and guide more targeted interventions for people facing the intersecting challenges of HIV, substance use, and mental illness.Apply for RFA DA 21 012
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Elucidation of mechanisms underlying complex morbidities of SUD and other mental Illnesses in people living with HIV/AIDS (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2020-10-16.
- Applicants must submit their applications by 2021-01-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education, Health
Next opportunity: Law Enforcement Co-Operation & Countering Violent Extremism Virtual Grant Program
Previous opportunity: Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 21 012
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 21 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Not Allowed) Apply for RFA CA 20 056 Funding Number: RFA CA 20 056 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed) Apply for PAR 20 236 Funding Number: PAR 20 236 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required) Apply for RFA CA 20 055 Funding Number: RFA CA 20 055 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Required) Apply for RFA CA 20 057 Funding Number: RFA CA 20 057 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) Apply for PAR 21 035 Funding Number: PAR 21 035 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) Apply for PAR 21 033 Funding Number: PAR 21 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 Clinical Trial Optional) Apply for PAR 21 023 Funding Number: PAR 21 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional) Apply for PAR 21 022 Funding Number: PAR 21 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R34 Clinical Trial Optional) Apply for RFA MH 21 150 Funding Number: RFA MH 21 150 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R01 Clinical Trial Optional) Apply for RFA MH 21 151 Funding Number: RFA MH 21 151 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) Apply for PAR 21 065 Funding Number: PAR 21 065 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) Apply for PAR 21 066 Funding Number: PAR 21 066 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) Apply for PAR 21 067 Funding Number: PAR 21 067 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed) Apply for RFA CA 21 003 Funding Number: RFA CA 21 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed) Apply for RFA CA 21 005 Funding Number: RFA CA 21 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 21 004 Funding Number: RFA CA 21 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 21 006 Funding Number: RFA CA 21 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional) Apply for RFA CA 21 009 Funding Number: RFA CA 21 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Apply for RFA CA 21 008 Funding Number: RFA CA 21 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) Apply for RFA CA 21 012 Funding Number: RFA CA 21 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 21 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
